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Abstract: Hepatocellular carcinoma, which has developed in liver cirrhosis is a disease where liver transplantation can provide a cure both for the
tumour and the underlying liver damage. However, patients can only be transplanted when the tumour number and size do not exceed the Milan
criteria. Tumour ablation methods – such as radiofrequency ablation – can provide a chance to make the patient eligible for transplantation. Among
the 416 Hungarian liver transplanted patients there are 6 who had received different types of ablative therapy as bridging therapy in different in-
stitutions. On the basis of analysis of the patients’ data we created a guideline for the treatment of cirrhotic patients with hepatocellular carcinoma
with the aim of developing a uniform Hungarian approach.
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Introduction
Hepatocellular carcinoma (HCC), is one of the most com-
mon cancers worldwide that usually develops in an already
damaged, often cirrhotic liver. Among others, the aetiol-
ogy of background liver disease is mainly cirrhosis caused
by chronic hepatitis B or C viral infection (HBV/HCV).
During treatment, not only HCC itself but also the back-
ground liver disease should be targeted. Liver transplanta-
tion (LT) guarantees the best long-term and disease-free
survival because it removes the cirrhotic liver with the tu-
mour. However, the shortage of organs only allows treat-
ing a small proportion of patients by LT [1, 2]. According
to the Milan criteria for liver transplantation with HCC, a
patient can only be transplanted if the nodule is not larger
than 5 cm or, in cases of multiplex nodules, if there is a
maximum of 3 nodules with the largest not exceeding 3
cm in diameter. Therefore disease progression produces a
25% dropout rate from the waiting lists [3].
Surgical and interventional treatments of HCC, known
as downstaging, are widely accepted as bridging therapies
to LT, in other words, as therapies with the ability to keep
patients on the waiting list [4]. Among the several abla-
tive methods, radiofrequency ablation (RFA) appears to
be one of the most efficient percutaneous technique for
HCC ablation. Other methods, such as percutaneous
ethanol infiltration (PEI) or transarterial chemoem-
bolization (TACE), are used with less favourable results
in terms of recurrence or tumour control [5, 6]. RFA
seems to be the best technique thanks to its predictable
area of induced necrosis and percentage of induced
necrotic cells [7].
In these RFA procedures, an ablation electrode at the
tip of a needle is placed percutaneously into the targeted
tumour under imaging guidance. Radiofrequency elec-
tromagnetic waves are transmitted from a generator and
converted to heat, thus inducing necrosis in the tissues
around the electrode.
The Hungarian Liver Transplant Program started in
1995, and during these years 416 LTs have been per-
formed [8]. RFA became available for downstaging in
2004, though with limited financial resources [9]. From
2004 until the end of 2008, several ablated patients un-
derwent successful LT, allowing their data to be analyzed.
The aim of this report is to determine important factors,
such as lesion number, size, histopathologic type, treat-
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ment type and time interval between treatment and LT,
based on explanted liver histology and to make important
refinements of patient selection and treatment protocol.
Patients and Methods
Between 2004 and 2008 we had six liver transplanted pa-
tients (2 females, 4 males, with a mean age of 56 years)
who were treated with RFA earlier. Five out of of six pa-
tients had HCV infection related cirrhosis and one had
ALD (alcoholic liver disease) related cirrhosis. None of the
patients had hepatitis B in their medical history. All the pa-
tients with HCV infection underwent targeted antiviral
therapy. There were three Child–Pugh Class A and three
Child–Pugh Class B patients. In these six patients nine
HCC nodules were identified with preoperative imaging
techniques, such as ultrasound (US), computed tomogra-
phy (CT) and magnetic resonance imaging (MRI). Eight
lesions were identifiable with US, eight with CT and six
with MRI. Pre-treatment fine needle aspiration biopsy
(FNAB) was performed in all patients but not in all lesions.
The bridging therapies and their follow-up imaging
tests were carried out in different medical centres. RFA
was guided by US (Fig. 1) in four patients, and with CT
(Fig. 2) in two patients. MRI guidance was not used,
since it is unavailable in Hungary. In three lesions of two
patients single 16-gauge open-perfused needle electrodes
(Berchtold Medizinelektronik) were applied. One patient
with one lesion was treated with the MIRAS device (In-
vatec) and three patients with five lesions (one, one and
three, respectively) were ablated with the RITA Starburst
system (Angiodynamics). One patient required general
anaesthesia, four patients were ablated under conscious
sedation, and one treatment could be performed under
local anaesthesia. Two patients received additional PEI
and one patient received chemoperfusion.
At follow-ups, multiphase contrast-enhanced CT scans
or MRI were performed. The mean time between initial
treatment and transplantation was 8.6 months (2–35
months) while the mean time between the last treatment
to transplantation was 10.2 months (2–35 months).
All the transplantations were performed from cadav-
eric donors; no living donation or split transplantation
were needed.
The explanted livers were processed and analyzed to
assess the degree of tumour necrosis and the signs of vas-
cular invasion (Fig. 3).
The mean post-transplant follow-up was 23.3 months
(3–46 months) (Table I).
Results
During the post-ablation follow-up period 4 lesions
showed complete necrosis whereas 5 lesions showed only
partial response on contrast-enhanced CT or MRI im-
ages. Histological examination of the explanted livers re-
vealed more than 14 countable lesions and in one patient
(Nr. 2) several additional small HCC nodules were
found. In this patient microscopic vascular invasion was
also diagnosed. The lesions were trabecular, except for
one that showed diffuse morphology. All of the lesions
were grade 2 or 3. Only one of the 9 lesions was com-
pletely necrotized at the time of transplantation, while in
7 lesions only partial necrosis could be found. One
treated nodule showed no necrosis at all.
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Fig. 1. Ultrasound-guided RFA ablation
Fig. 2. CT-guided RFA ablation. Non contrast CT shows the tip of
the needle at the border of the tumour. Follow-up contrast
enhanced CT image shows complete necrosis
Fig. 3. Necrosis in the tumour in the explanted liver
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The time interval between the first and the last treat-
ment and the liver transplantation was 8.6 and 10.2
months, respectively, but patient Nr. 2 had a time inter-
val of 35.5 months, during which period the above-men-
tioned multilocular recurrences were able to develop.
All the liver transplantations were successful, without ev-
idence of vascular and/or biliary complications. One re-
operation was performed due to postoperative bleeding,
and one patient developed small bowel perforation 3 weeks
after transplantation, necessitating surgical intervention.
For the time being, four out of six patients are fine with
acceptable liver function tests and no signs of recurrence
or metastasis. One patient (Nr. 4) with a larger HCC (ini-
tial size: 51 mm) recently developed extrahepatic (left
pleural) HCC recurrence and the second patient (Nr. 6)
(initial size: 75 mm) retroperitoneal HCC recurrence
after 41.6 and 12.1 months, respectively. These two pa-
tients waited for transplantation for more than 6 months
(7.4 and 6.5 months). The third patient (Nr. 1), with a
longer waiting time, has the shortest follow-up. There
was no obvious relationship between recurrence and im-
munosupression, or tumour characteristics in this small
group of patients.
Discussion
Small and medium sized HCC accompanied with end-
stage liver cirrhosis can be most effectively treated with
liver transplantation (LT). Theoretically, transplantation
might simultaneously cure the tumour and the underly-
ing cirrhosis. Candidates who are eligible for LT should
have one HCC smaller than 5 cm or the maximum of
three nodules that are smaller than 3 cm [10] and can
achieve a 70% survival rate at 5 years, with a recurrence
rate lower than 15%. Tumour progression on the waiting
list is a crucial point worldwide, because the benefit of
transplantation could only be obtained if the waiting time
does not exceed 6 months [11]. The shortage of donors
clearly limits the potential benefits of cadaveric liver trans-
plantation [1]. Various methods have been available to re-
duce the dropout-rate from the waiting list by applying
adjuvant therapies for HCC. Liver resection can be per-
formed in cases with preserved liver function, followed by
salvage liver transplantation [12, 13]. There are reports
demonstrating the effectiveness of chemoembolization
[14, 15]. Local ablation therapies for HCC, such as PEI
and RFA, can be performed safely and effectively in com-
pensated cirrhosis [16]. Furthermore, combinations of
therapies could also be an option in selected cases [17].
In a study by Yamashiki et al., 288 patients with HCC
on a virtual waiting list were treated. The authors ana-
lyzed the risk factors of tumour recurrence and dropout.
They treated the recurrent HCCs every time when it
was possible. Their results proved the beneficial effects
of the ablative therapy on the rate of dropouts (9% at 1
year), and showed that an alpha-fetoprotein (AFP) level
of more than 100 ng/mL or a des-c-carboxy pro-
thrombin (DCP) level of more than 100 mAU/mL, and
HCC downstaging with RFA for l iver transplantation
Table I. Relevant data of six patients who underwent ablative downstaging before orthotopic liver transplantation
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1 B yes no 6.5 3.7 2× RFA 1 2 partial partial no 43 FK+steroid
+Eve
2.7 no no
2 A yes no 35.5 35.5 1× RFA 1 multilocular complete,
but
recurrence
minimal yes 26 FK+steroid
+MMF
10.2 no no
3 A yes no 2 2 1× RFA 1 1+1 DN one partial
(80%)
66% no 32 CyA+ste-
roid+MMF
26.8 no no
4 B yes no 7.4 2.4 1×
RFA+2×
PEI
1 2 one partial,
(90%)
60% no 51 FK+steroid
+MMF
41.6 yes no
5 A yes no 3.5 1.5 1×
RFA+4×
ChP
2 2 complete partial no 22 FK+steroid
+MMF
46.5 no no
6 B no no 6.5 6.3 1×
RFA+1×
PEI
3 2+4 DN two
partial,
one
complete
50%/100%,
no necrosis
in 1 DN
no 75 FK+steroid
+MMF,
later
FK+Eve
12.1 yes no
10.2 8.6 14.0 9 >14 1 41.5 23.3 2 0
(Abbreviations: HCV/HBV – hepatitis C/B viral infection; LT – liver transplantation; DT – time interval between treatments and LT; RFA – radiofrequency ablation;
PEI – percutaneous ethanol infiltration; ChP – chemoperfusion; DN – high grade dysplastic nodule; PVT – portal vein thrombosis/invasion; FK – FK-506; MMF –
mycophenolate mofetil; Eve – everolimus)
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a tumour size exceeding 3 cm (most likely due to mi-
crovascular invasion), were associated with a high prob-
ability of dropout due to tumour progression [18]. Sim-
ilar results were presented in a retrospective study by
Pompili et al., where 46 HCC were treated with ablative
techniques (RFA and/or PEI) before transplantation,
and after 9.5 months of mean waiting time the ex-
planted livers were pathologically analyzed. The authors
focused on the degree of necrosis, as a measure of the
success of ablation procedure and as a factor of pro-
longed recurrence-free survival. Complete necrosis was
found only in 43% of the treated nodules, but the rate
was higher after RFA (53%). Again the best results were
achieved when lesions with a diameter of less than 3 cm
were ablated with RFA [19].
Our preliminary experience shows similar results to
that of the larger reports. Patients with larger tumours
and longer waiting times had worse results in terms of
post-transplantation recurrence. The relationship be-
tween the degree of necrosis and time interval is not as-
sessable. Because of the small number of patients and
the limited availability of the thermoablative methods, it
is not possible to analyze the impact of these ablative
therapies on the dropout rate from the Hungarian wait-
ing list.
We used our results combined with the results of the
literature to develop a tailored future guideline for the
adjuvant treatment of cirrhotic HCC patients waiting for
transplantation. This guideline was based on the
Barcelona Clinic Liver Cancer Group (BCLC) classifica-
tion [1] and the Milan criteria [10], with additional fac-
tors, such as tumour characteristics, periodicity of the fol-
low-up, and repeated treatments [20].
At present the guideline includes the following state-
ments:
– For Child–Pugh Class A-B patients on the waiting list
with liver cirrhosis and tumours within the Milan cri-
teria and without portal or hepatic vein invasion: If re-
section is not possible, ablation should be performed as
bridging therapy when the treatable nodule size is less
than 3 cm, while chemoembolization or combined
therapy should be carried out when the size of the tu-
mour is 3–5 cm. Combined therapy should also be pre-
ferred when complete necrosis is not achievable with
ablation(s) alone. Follow-up examinations should be
adequate (multiphase contrast-enhanced imaging, tu-
mour markers), and should be repeated every 3
months. In case of diagnosed recurrence or new HCC
re-treatment should be attempted.
– For patients being evaluated for liver transplantation
with HCC exceeding the Milan criteria and with a liver
function precluding resection: the therapeutic meth-
ods as above should be discussed for downstaging.
A successful therapy may allow the patient to enter the
waiting list, but risk factors for early post-transplanta-
tion recurrence should also be assessed. In these cases,
pre-treatment histopathologic staging may help in
proper selection of patients for treatment.
The uniform use of this guideline would allow to refine
this approach and assess the results. Therefore the guide-
line has to be re-evaluated in every year and updated as
ablative and embolization technology innovations and
new drugs are becoming available.
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